Profile data is unavailable for this security.
About the company
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.
- Revenue in USD (TTM)8.32m
- Net income in USD-23.28m
- Incorporated1998
- Employees48.00
- LocationDURECT Corp10240 Bubb RoadCUPERTINO 95014United StatesUSA
- Phone+1 (408) 777-1417
- Fax+1 (408) 777-3577
- Websitehttps://www.durect.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gain Therapeutics Inc | 0.00 | -21.14m | 45.13m | 29.00 | -- | 5.22 | -- | -- | -1.53 | -1.53 | 0.00 | 0.479 | 0.00 | -- | -- | 0.00 | -117.80 | -- | -164.29 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0555 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
Ocuphire Pharma Inc | 19.01m | -11.30m | 45.37m | 14.00 | -- | 0.9532 | -- | 2.39 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
Aligos Therapeutics Inc | 13.79m | -99.59m | 46.83m | 67.00 | -- | 0.7896 | -- | 3.40 | -1.51 | -1.51 | 0.1796 | 0.7592 | 0.1105 | -- | -- | 208,969.70 | -79.78 | -51.20 | -98.27 | -59.73 | -- | -- | -722.06 | -1,399.21 | -- | -- | 0.0037 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
Inotiv Inc | 552.74m | -71.29m | 47.01m | 1.96k | -- | 0.2263 | -- | 0.085 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
CASI Pharmaceuticals Inc | 28.94m | -30.48m | 47.04m | 176.00 | -- | 3.04 | -- | 1.63 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
Carisma Therapeutics Inc | 15.07m | -81.22m | 47.77m | 107.00 | -- | 4.38 | -- | 3.17 | -2.01 | -2.01 | 0.3723 | 0.2623 | 0.1311 | -- | -- | 140,869.20 | -70.64 | -30.87 | -83.17 | -34.47 | -- | -- | -538.81 | -255.66 | -- | -- | 0.1717 | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
Arca Biopharma Inc | 0.00 | -6.00m | 48.02m | 4.00 | -- | 1.37 | -- | -- | -0.4155 | -0.4155 | 0.00 | 2.42 | 0.00 | -- | -- | 0.00 | -15.24 | -27.78 | -15.81 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
Incannex Healthcare Inc | -100.00bn | -100.00bn | 48.73m | -- | -- | 3.45 | -- | -- | -- | -- | -- | 0.8907 | -- | -- | -- | -- | -- | -54.94 | -- | -59.47 | -- | -- | -- | -1,033.07 | -- | -- | 0.00 | -- | 61.92 | 3.38 | -24.35 | -- | 54.12 | -- |
DURECT Corp | 8.32m | -23.28m | 48.73m | 48.00 | -- | 5.87 | -- | 5.86 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
Lexaria Bioscience Corp | 404.72k | -5.44m | 49.09m | 5.00 | -- | 7.24 | -- | 121.30 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
Modular Medical Inc | 0.00 | -16.76m | 49.74m | 37.00 | -- | 8.89 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
Moolec Science SA | 2.65m | -52.66m | 50.08m | 45.00 | -- | 4.94 | -- | 18.93 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
Kezar Life Sciences Inc | 7.00m | -101.87m | 50.82m | 58.00 | -- | 0.2708 | -- | 7.26 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 51.11m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
Eagle Pharmaceuticals Inc | 257.55m | 11.95m | 51.95m | 134.00 | 4.39 | 0.2078 | 1.59 | 0.2017 | 0.911 | 0.911 | 19.59 | 19.25 | 0.6549 | 1.55 | 2.56 | 1,922,022.00 | 3.04 | 6.37 | 4.04 | 7.98 | 69.84 | 71.86 | 4.64 | 7.85 | 1.67 | 3.55 | 0.2178 | 0.00 | 84.56 | 5.99 | 513.14 | -8.42 | -49.05 | -- |
Holder | Shares | % Held |
---|---|---|
Ingalls & Snyder LLCas of 31 Mar 2024 | 2.02m | 6.50% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.07m | 3.46% |
Richmond Brothers, Inc.as of 31 Mar 2024 | 768.34k | 2.48% |
Gagnon Securities LLCas of 31 Mar 2024 | 380.13k | 1.23% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 339.72k | 1.10% |
Geode Capital Management LLCas of 31 Mar 2024 | 293.15k | 0.95% |
Beirne Wealth Consulting Services LLCas of 31 Mar 2024 | 283.01k | 0.91% |
Montchanin Asset Management LLCas of 31 Mar 2024 | 270.10k | 0.87% |
Tocqueville Asset Management LPas of 31 Mar 2024 | 256.22k | 0.83% |
GSA Capital Partners LLPas of 31 Mar 2024 | 241.67k | 0.78% |